The Curious Constraints on Clofazimine

Despite decades of safe use, access to clofazimine, a WHO-recommended treatment for leprosy and emerging therapy for drug-resistant tuberculos,remains limited in the US and other high income countries due to reliance on a single manufacturer and complex expanded access pathways. Streamlining regulatory and procurement processes, as well as expanded public manufacturing capcity, can help ensure equitable supply of this essential medicine.